Reversible Lysine Covalent Modifiers for Selective CDK2 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing selective CDK2 modulators has been challenging due to the similarity of CDK2 with other cyclin-dependent kinases, and there are no approved agents targeting CDK2, which is associated with poor outcomes in various cancers.
Innovation Solution
The development of reversible lysine covalent modifiers, represented by compounds of Formula (I) and (II), which selectively target CDK2 by forming covalent bonds with lysine residues, modulating CDK2 activity and inhibiting its function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CDK inhibitors are used, then CDK activity is inhibited, but selectivity for CDK2 is lost due to structural similarity among CDKs
Solution Approach 1:
The patent introduces a localized electrophilic warhead at a specific position in the inhibitor molecule that targets a unique lysine residue in the CDK2 active site. This localized modification creates selective covalent bonding capability for CDK2 while preserving non-covalent interactions that provide overall binding affinity, thereby achieving selectivity without sacrificing binding strength.
Solution Approach 2:
The patent changes the chemical reactivity parameter of the inhibitor by incorporating an electrophilic warhead that forms reversible covalent bonds with lysine residues. This parameter change allows the inhibitor to exploit subtle differences in the electrostatic potential and residue accessibility among CDK isoforms, enabling selective targeting of CDK2 over other CDKs.
2Strength
If irreversible covalent inhibitors are used, then binding affinity is increased, but reversibility and safety are compromised
Solution Approach 1:
The patent employs a dynamic covalent bond that can form and break under physiological conditions. The electrophilic warhead forms a covalent bond with the lysine residue, providing strong binding affinity, but the bond remains reversible through hydrolysis or exchange reactions, allowing the inhibitor to be cleared and reducing the risk of permanent off-target effects.
Solution Approach 2:
The patent changes the kinetic stability parameter of the covalent bond by selecting electrophilic warheads with controlled reactivity. The bond formation is sufficiently strong to provide potent inhibition, but the bond lability is tuned to allow reversibility under physiological conditions, balancing binding strength with safety.
3Reliability
If highly reactive electrophilic warheads are used, then covalent bond formation is enhanced, but off-target reactivity and toxicity increase
Solution Approach 1:
The patent confines the electrophilic reactivity to a specific localized region (the warhead) that is positioned to interact with a unique lysine residue in CDK2. The rest of the molecule is designed with electron-withdrawing groups that reduce overall reactivity, thereby enhancing selectivity and reducing off-target effects while maintaining covalent bond formation capability.
Solution Approach 2:
The patent uses the electrophilic warhead as an intermediary that mediates selective covalent bonding. The warhead's reactivity is modulated by its electronic environment and steric accessibility, allowing it to preferentially react with the target lysine residue in CDK2 while avoiding reaction with other proteins. The reversible nature of the bond further reduces off-target toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively inhibit CDK2 activity, providing a potential therapeutic approach for treating cancers mediated by CDK2, including breast, ovarian, and gastric cancers, by modulating cell proliferation.
Implementation Method 1
R5 is selected from an electrophilic moiety or a prodrug thereof... the electrophilic moiety reacts with a lysine residue of CDK2 to form a covalent bond
Data Source
AI summary
In some aspects, the present disclosure provides compounds of Formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), or pharmaceutically acceptable salts thereof, for the modulation of CDK2. In another aspect, the present disclosure provides methods for the treatment of diseases or disorders mediated by CDK2, such as oncology indications, using compounds of Formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), or pharmaceutically acceptable salts thereof.